Sphera Funds Management’s Neurogene NGNE Stock Holding History

Sphera Funds Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,850	Closed	-$4.52M	–	102
2020 Q1	$4.52M	Buy	19,850 +850	+4%	+$175K	0.57%	40
2019 Q4	$4.68M	Buy	+19,000	New	+$1.89M	0.39%	59
2018 Q3	–	Sell	-12,881	Closed	-$683K	–	123
2018 Q2	$683K	Buy	12,881 +9,104	+241%	+$2.37M	0.09%	94
2018 Q1	$1.06M	Hold	3,777	–	–	0.16%	83
2017 Q4	$888K	Hold	3,777	–	–	0.1%	115
2017 Q3	$1.07M	Buy	3,777 +673	+22%	+$193K	0.15%	101
2017 Q2	$874K	Buy	+3,104	New	+$888K	0.15%	106
2014 Q3	–	Sell	-9,500	Closed	-$1.78M	–	137
2014 Q2	$1.78M	Hold	9,500	–	–	0.44%	55
2014 Q1	$2.42M	Buy	+9,500	New	+$2.44M	0.55%	37

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Sphera Funds Management's NGNE Position: Q2 2020 in Review

Sphera Funds Management sold out of Neurogene (NGNE) in Q2 2020, closing a stake of 19,850 shares — an estimated $4.52M sold.

Sphera Funds Management first reported a position in NGNE in Q1 2014 and held it in 9 quarters. The position peaked at $4.68M in Q4 2019. 74 funds tracked by Wall St. Rank hold NGNE as of Q2 2020.

Sphera Funds Management reported no remaining Neurogene position as of Q2 2020 after selling out during the quarter.
Sphera Funds Management sold 19,850 Neurogene shares in Q2 2020, an estimated $4.52M.
Sphera Funds Management first reported a position in Neurogene in Q1 2014 and held it in 9 quarters.
Sphera Funds Management's Neurogene position peaked at $4.68M in Q4 2019.
74 funds tracked by Wall St. Rank held Neurogene as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.